Symbols / INMB Stock $1.22 +0.83% INmune Bio Inc.

Healthcare • Biotechnology • United States • NCM
INMB (Stock) Chart
About

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 32.43M
Enterprise Value 8.45M Income -45.93M Sales 50.00K
Book/sh 0.89 Cash/sh 0.93 Dividend Yield —
Payout 0.00% Employees 21 IPO —
P/E — Forward P/E -1.56 PEG —
P/S 648.68 P/B 1.38 P/C —
EV/EBITDA -0.28 EV/Sales 169.02 Quick Ratio 3.48
Current Ratio 3.55 Debt/Eq 4.40 LT Debt/Eq —
EPS (ttm) -1.86 EPS next Y -0.78 EPS Growth —
Revenue Growth — Earnings 2026-05-14 ROA -53.66%
ROE -165.16% ROIC — Gross Margin 100.00%
Oper. Margin -617.38% Profit Margin 0.00% Shs Outstand 26.59M
Shs Float 20.61M Short Float 16.03% Short Ratio 6.00
Short Interest — 52W High 11.64 52W Low 1.09
Beta 0.89 Avg Volume 435.91K Volume 53.37K
Target Price $7.00 Recom Strong_buy Prev Close $1.21
Price $1.22 Change 0.83%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.00
Mean price target
2. Current target
$1.25
Latest analyst target
3. DCF / Fair value
$-8.82
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.25
Low
$4.00
High
$9.00
Mean
$7.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-11 up LUCID CAPITAL MARKETS Neutral → Buy $9
2025-07-02 main Maxim Group Buy → Buy $8
2025-07-01 down BTIG Buy → Neutral —
2025-07-01 down Scotiabank Sector Outperform → Sector Underperform $1
2025-02-13 main Maxim Group Buy → Buy $30
2025-02-11 main Scotiabank Sector Outperform → Sector Outperform $23
2023-06-01 init Baird — → Outperform $16
2022-05-24 main BTIG — → Buy $14
2022-05-24 down B. Riley Securities Buy → Neutral $7
2022-01-24 main B. Riley Securities — → Buy $20
2021-04-21 init B. Riley Securities — → Buy $29
2020-11-09 main HC Wainwright & Co. — → Buy $15
2020-09-01 init BTIG — → Buy $23
2020-07-15 main HC Wainwright & Co. — → Buy $20
2020-05-15 reit HC Wainwright & Co. — → Buy $8
2020-03-12 main HC Wainwright & Co. — → Buy $8
2019-12-19 init Roth Capital — → Buy $13
2019-08-21 init HC Wainwright & Co. — → Buy $12
2019-03-19 init Maxim Group — → Buy —
News
RSS: Latest INMB news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-09-30 MOSS DAVID J. Chief Financial Officer — 10,000 $5.29 $52,868
2024-09-12 TESI RAYMOND JOSEPH Chief Executive Officer — 15,380 $6.38 $98,048
2024-09-12 MOSS DAVID J. Chief Financial Officer — 7,690 $6.38 $49,024
2024-06-25 JUDA SCOTT Director — 5,000 $7.27 $36,350
2024-04-19 TESI RAYMOND JOSEPH Chief Executive Officer — 18,028 $8.32 $149,993
2024-04-19 MOSS DAVID J. Chief Financial Officer — 18,028 $8.32 $149,993
2024-04-19 LOWDELL MARK WILLIAM Officer and Beneficial Owner of more than 10% of a Class of Security — 14,423 $8.32 $119,999
2024-04-19 JUDA SCOTT Director — 29,603 $8.32 $246,297
2024-04-19 TESI RAYMOND JOSEPH Chief Executive Officer — 18,028 $8.32 $149,993
2024-04-19 MOSS DAVID J. Chief Financial Officer — 18,028 $8.32 $149,993
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.05
+257.14%
0.01
-90.97%
0.15
-58.56%
0.37
Operating Revenue
0.05
+257.14%
0.01
-90.97%
0.15
-58.56%
0.37
Operating Expense
30.92
-27.50%
42.65
+42.66%
29.90
+13.57%
26.32
Research And Development
20.66
-37.71%
33.17
+63.60%
20.27
+18.78%
17.07
Selling General And Administration
10.26
+8.19%
9.48
-1.45%
9.62
+3.94%
9.26
General And Administrative Expense
10.26
+8.19%
9.48
-1.45%
9.62
+3.94%
9.26
Other Gand A
10.26
+8.19%
9.48
-1.45%
9.62
+3.94%
9.26
Total Expenses
30.92
-27.50%
42.65
+42.66%
29.90
+13.57%
26.32
Operating Income
-30.87
+27.60%
-42.63
-43.35%
-29.74
-14.60%
-25.95
Total Operating Income As Reported
-47.38
-11.14%
-42.63
-43.35%
-29.74
-14.60%
-25.95
EBITDA
-30.79
+27.79%
-42.63
-43.35%
-29.74
-14.60%
-25.95
Normalized EBITDA
-14.27
+66.53%
-42.63
-43.35%
-29.74
-14.60%
-25.95
Reconciled Depreciation
0.08
0.00
—
—
EBIT
-30.87
+27.60%
-42.63
-43.35%
-29.74
-14.60%
-25.95
Total Unusual Items
-16.51
0.00
—
—
Total Unusual Items Excluding Goodwill
-16.51
0.00
—
—
Special Income Charges
-16.51
0.00
—
—
Impairment Of Capital Assets
16.51
0.00
—
—
Net Income
-45.93
-9.15%
-42.08
-40.24%
-30.01
-9.92%
-27.30
Pretax Income
-45.93
-9.15%
-42.08
-40.24%
-30.01
-9.92%
-27.30
Other Income Expense
-15.06
-2824.05%
0.55
+307.12%
-0.27
+80.19%
-1.35
Other Non Operating Income Expenses
1.45
+162.21%
0.55
+307.12%
-0.27
+80.19%
-1.35
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-45.93
-9.15%
-42.08
-40.24%
-30.01
-9.92%
-27.30
Net Income From Continuing Operation Net Minority Interest
-45.93
-9.15%
-42.08
-40.24%
-30.01
-9.92%
-27.30
Net Income From Continuing And Discontinued Operation
-45.93
-9.15%
-42.08
-40.24%
-30.01
-9.92%
-27.30
Net Income Continuous Operations
-45.93
-9.15%
-42.08
-40.24%
-30.01
-9.92%
-27.30
Normalized Income
-29.42
+30.09%
-42.08
-40.24%
-30.01
-9.92%
-27.30
Net Income Common Stockholders
-45.93
-9.15%
-42.08
-40.24%
-30.01
-9.92%
-27.30
Diluted EPS
—
-2.11
-26.35%
-1.67
-9.87%
-1.52
Basic EPS
—
-2.11
-26.35%
-1.67
-9.87%
-1.52
Basic Average Shares
—
19.94
+10.92%
17.98
+0.30%
17.93
Diluted Average Shares
—
19.94
+10.92%
17.98
+0.30%
17.93
Diluted NI Availto Com Stockholders
-45.93
-9.15%
-42.08
-40.24%
-30.01
-9.92%
-27.30
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
32.35
-18.23%
39.56
-30.59%
57.00
-30.31%
81.80
Current Assets
29.89
+31.88%
22.66
-43.26%
39.94
-38.24%
64.67
Cash Cash Equivalents And Short Term Investments
24.75
+18.30%
20.92
-41.64%
35.85
-31.26%
52.15
Cash And Cash Equivalents
24.75
+18.30%
20.92
-41.64%
35.85
-31.26%
52.15
Cash Financial
—
—
—
—
Receivables
4.54
+222.29%
1.41
-42.30%
2.44
-71.14%
8.46
Taxes Receivable
4.54
+222.29%
1.41
-42.30%
2.44
-71.14%
8.46
Prepaid Assets
—
0.00
-100.00%
0.14
+317.65%
0.03
Other Current Assets
0.59
+79.76%
0.33
-78.08%
1.51
-62.50%
4.03
Total Non Current Assets
2.46
-85.42%
16.90
-0.93%
17.06
-0.36%
17.12
Net PPE
1.87
+508.79%
0.31
-25.85%
0.41
-18.34%
0.51
Gross PPE
1.87
+508.79%
0.31
-25.85%
0.41
-18.34%
0.51
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.91
+197.72%
0.31
-25.85%
0.41
-18.34%
0.51
Other Properties
0.95
—
—
—
Goodwill And Other Intangible Assets
0.00
-100.00%
16.51
+0.00%
16.51
+0.00%
16.51
Other Intangible Assets
—
16.51
+0.00%
16.51
+0.00%
16.51
Other Non Current Assets
0.59
+653.16%
0.08
-39.69%
0.13
+32.32%
0.10
Total Liabilities Net Minority Interest
8.83
+18.25%
7.46
-60.42%
18.86
-13.04%
21.69
Current Liabilities
8.42
+16.55%
7.22
-60.89%
18.46
+69.12%
10.92
Payables And Accrued Expenses
7.79
+18.72%
6.56
-17.29%
7.94
+52.18%
5.21
Payables
7.79
+18.72%
6.56
-17.29%
7.94
+52.18%
5.21
Accounts Payable
7.79
+18.72%
6.56
-17.29%
7.94
+52.18%
5.21
Current Debt And Capital Lease Obligation
0.62
+345.00%
0.14
-98.61%
10.04
+97.37%
5.09
Current Debt
—
—
9.92
+98.42%
5.00
Other Current Borrowings
—
—
9.92
+98.42%
5.00
Current Capital Lease Obligation
0.62
+345.00%
0.14
+17.65%
0.12
+36.78%
0.09
Current Deferred Liabilities
0.00
-100.00%
0.52
+5.73%
0.49
-20.62%
0.62
Total Non Current Liabilities Net Minority Interest
0.41
+68.44%
0.24
-38.54%
0.40
-96.31%
10.77
Long Term Debt And Capital Lease Obligation
0.41
+68.44%
0.24
-38.54%
0.40
-96.12%
10.22
Long Term Debt
—
—
—
9.70
Long Term Capital Lease Obligation
0.41
+68.44%
0.24
-38.54%
0.40
-24.52%
0.53
Stockholders Equity
23.52
-26.71%
32.10
-15.84%
38.14
-36.54%
60.10
Common Stock Equity
23.52
-26.71%
32.10
-15.84%
38.14
-36.54%
60.10
Capital Stock
0.03
+22.73%
0.02
-97.31%
0.82
+4438.89%
0.02
Common Stock
0.03
+22.73%
0.02
-97.31%
0.82
+4438.89%
0.02
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
26.59
+19.32%
22.28
+24.12%
17.95
+0.03%
17.95
Ordinary Shares Number
26.59
+19.32%
22.28
+24.12%
17.95
+0.03%
17.95
Additional Paid In Capital
233.27
+19.17%
195.75
+23.01%
159.14
+4.84%
151.80
Retained Earnings
-209.04
-28.16%
-163.10
-34.77%
-121.02
-32.97%
-91.01
Gains Losses Not Affecting Retained Earnings
-0.74
-28.17%
-0.57
+28.04%
-0.80
-14.31%
-0.70
Other Equity Adjustments
-0.74
-28.17%
-0.57
+28.04%
-0.80
-14.31%
-0.70
Total Equity Gross Minority Interest
23.52
-26.71%
32.10
-15.84%
38.14
-36.54%
60.10
Total Capitalization
23.52
-26.71%
32.10
-15.84%
38.14
-45.36%
69.80
Working Capital
21.47
+39.05%
15.44
-28.10%
21.48
-60.05%
53.76
Invested Capital
23.52
-26.71%
32.10
-33.21%
48.06
-35.75%
74.80
Total Debt
1.03
+169.27%
0.38
-96.32%
10.44
-31.83%
15.31
Capital Lease Obligations
1.03
+169.27%
0.38
-25.58%
0.52
-15.82%
0.61
Net Tangible Assets
23.52
+50.96%
15.58
-27.94%
21.62
-50.39%
43.59
Tangible Book Value
23.52
+50.96%
15.58
-27.94%
21.62
-50.39%
43.59
Non Current Accrued Expenses
—
—
0.00
-100.00%
0.55
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-22.58
+32.31%
-33.36
-178.47%
-11.98
+47.19%
-22.69
Cash Flow From Continuing Operating Activities
-22.58
+32.31%
-33.36
-178.47%
-11.98
+47.19%
-22.69
Net Income From Continuing Operations
-45.93
-9.15%
-42.08
-40.24%
-30.01
-9.92%
-27.30
Depreciation Amortization Depletion
0.08
0.00
—
—
Depreciation
0.08
0.00
—
—
Depreciation And Amortization
0.08
0.00
—
—
Other Non Cash Items
-0.63
-892.41%
0.08
-64.73%
0.22
-6.28%
0.24
Stock Based Compensation
9.91
+30.31%
7.61
+3.22%
7.37
+3.06%
7.15
Asset Impairment Charge
16.51
0.00
0.00
-100.00%
0.09
Change In Working Capital
-2.53
-344.07%
1.04
-90.06%
10.44
+464.39%
-2.86
Change In Receivables
-3.13
-403.19%
1.03
-82.84%
6.02
+303.55%
-2.96
Change In Prepaid Assets
-0.26
-119.98%
1.32
-45.16%
2.41
+236.18%
-1.77
Change In Payables And Accrued Expense
1.85
+235.20%
-1.37
-163.20%
2.17
+23.84%
1.75
Change In Accrued Expense
—
0.00
+100.00%
-0.55
-256.70%
0.35
Change In Payable
1.85
+235.20%
-1.37
-150.42%
2.72
+94.08%
1.40
Change In Account Payable
1.85
+235.20%
-1.37
-150.42%
2.72
+94.08%
1.40
Change In Other Working Capital
-0.52
-1946.43%
0.03
+122.05%
-0.13
-189.44%
0.14
Change In Other Current Assets
-0.52
-1092.31%
0.05
+262.50%
-0.03
0.00
Change In Other Current Liabilities
0.04
+272.00%
-0.03
-525.00%
-0.00
+87.88%
-0.03
Investing Cash Flow
-1.04
0.00
—
0.00
Cash Flow From Continuing Investing Activities
-1.04
0.00
—
0.00
Net PPE Purchase And Sale
-1.04
0.00
—
—
Purchase Of PPE
-1.04
0.00
—
—
Capital Expenditure
-1.04
—
—
—
Net Intangibles Purchase And Sale
—
—
—
0.00
Purchase Of Intangibles
—
—
—
0.00
Financing Cash Flow
27.61
+51.62%
18.21
+531.03%
-4.22
-679.56%
0.73
Cash Flow From Continuing Financing Activities
27.61
+51.62%
18.21
+531.03%
-4.22
-679.56%
0.73
Net Issuance Payments Of Debt
0.00
+100.00%
-10.00
-100.00%
-5.00
0.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
0.00
+100.00%
-10.00
-100.00%
-5.00
0.00
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
0.00
+100.00%
-10.00
-100.00%
-5.00
0.00
Net Long Term Debt Issuance
0.00
+100.00%
-10.00
-100.00%
-5.00
0.00
Net Common Stock Issuance
27.54
-0.88%
27.79
+3485.68%
0.78
+10.87%
0.70
Common Stock Payments
—
—
—
—
Repurchase Of Capital Stock
—
—
—
—
Proceeds From Stock Option Exercised
0.07
-83.89%
0.42
0.00
-100.00%
0.03
Changes In Cash
3.99
+126.32%
-15.15
+6.51%
-16.20
+26.20%
-21.96
Effect Of Exchange Rate Changes
-0.16
-170.98%
0.22
+324.00%
-0.10
+85.71%
-0.70
Beginning Cash Position
20.92
-41.64%
35.85
-31.26%
52.15
-30.29%
74.81
End Cash Position
24.75
+18.30%
20.92
-41.64%
35.85
-31.26%
52.15
Free Cash Flow
-23.62
+29.19%
-33.36
-178.47%
-11.98
+47.19%
-22.69
Interest Paid Supplemental Data
0.00
-100.00%
1.69
-4.95%
1.78
+29.59%
1.37
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Common Stock Issuance
27.54
-0.88%
27.79
+3485.68%
0.78
+10.87%
0.70
Issuance Of Capital Stock
27.54
-0.88%
27.79
+3485.68%
0.78
+10.87%
0.70
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category